Clinical trials referenced in this document:
Documents that mention this clinical trial
Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA032552, R01DA032552)
Received: 19 May 2021
Accepted: 12 October 2021
First Online: 24 October 2021
: The trial was approved by the Institutional Review Boards of both Albert Einstein College of Medicine/Montefiore Medical Center and Fordham University. Informed consent was collected for all participants in this study.
: Not applicable.
: The authors declare that they have no competing interests.